A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Summary

This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.

Timeline

Start

2019-08-12

Primary completion

2021-04-26

Completion

2021-04-26

Drugs

Indications